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Background: Mutant Ras plays multiple functions in tumorigenesis including tumor formation and metastasis.
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a metastasis inhibitor gene, suppresses matrix
metalloproteinase (MMP) activity in the metastatic cascade. Clarifying the relationship between Ras and RECK
and understanding the underlying molecular mechanism may lead to the development of better treatment for
Ras-related tumors.
Methods: Suppression subtractive hybridization PCR (SSH PCR) was conducted to identify Ha-rasval12 up-regulated
genes in bladder cancer cells. Stable cell lines of human breast cancer (MCF-7-ras) and mouse NIH3T3 fibroblasts
(7–4) harboring the inducible Ha-rasval12 oncogene, which could be induced by isopropylthio-β-D-galactoside (IPTG),
were used to clarify the relationship between Ras and the up-regulated genes. Chromatin immunoprecipitation
(ChIP) assay, DNA affinity precipitation assay (DAPA) and RECK reporter gene assay were utilized to confirm the
complex formation and binding with promoters.
Results: Retinoblastoma binding protein-7 (RbAp46) was identified and confirmed as a Ha-rasval12 up-regulated
gene. RbAp46 could bind with histone deacetylase (HDAC1) and Sp1, followed by binding to RECK promoter at the
Sp1 site resulting in repression of RECK expression. High expression of Ras protein accompanied with high RbAp46
and low RECK expression were detected in 75% (3/4) of the clinical bladder cancer tumor tissues compared to
the adjacent normal parts. Ras induced RbAp46 expression increases invasion of the bladder cancer T24 cells and
MMP-9 activity was increased, which was confirmed by specific lentiviral shRNAs inhibitors against Ras and RbAp46.
Similarly, knockdown of RbAp46 expression in the stable NIH3T3 cells “7-4” by shRNA decreased Ras-related lung
metastasis using a xenograft nude mice model.
Conclusions: We confirmed that RbAp46 is a Ha-rasval12 up-regulated gene and binds with HDAC1 and Sp1.
Furthermore, RbAp46 binds to the RECK promoter at the Sp1 site via recruitment by Sp1. RECK is subsequently
activated, leading to increased MMP9 activity, which may lead to increased metastasis in vivo. Our findings of Ras
upregulation of RbAp46 may lead to revealing a novel mechanism of Ras-related tumor cell metastasis.
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H-ras, K-ras, and N-ras proteins are members of a large
superfamily of low-molecular-weight GTP-binding pro-
teins which control signaling pathways that are key regu-
lators of numerous aspects of normal cell growth and
malignant transformation [1]. About 30% of human tu-
mors express Ras point mutations [2]. At least three major
effectors of Ras are responsible for downstream signal
transduction, including the Raf/mitogen-activated protein
kinase (MAPK) pathway, the phosphatidylinositol 3-
kinases (PI3Ks) pathway and the Ral guanine nucleotide
exchange factors (RalGEFs) pathway [3]. Contributions
of these pathways are mainly observed in tumor initi-
ation, such as cell survival, proliferation and transform-
ation. However, little is known about their involvement
in Ras-induced cell invasion and metastasis. Moreover,
the roles of mediators in Ras induction of invasion and
metastasis are not fully understood [4]. Therefore, the
precise effects of Ras-related factors and their functions
in tumorigenesis warrant further investigation.
The reversion-inducing cysteine-rich protein with Kazal
motifs (RECK) gene is a membrane-anchored glycoprotein
that negatively regulates matrix metalloproteinases (MMPs)
and inhibits tumor metastasis and angiogenesis [5,6]. The
RECK gene was first isolated as a transformation suppres-
sor gene to induce flat reversion in a v-Ki-ras-transformed
NIH3T3 cell line [5]. Further studies showed that RECK is
down-regulated in many human cancers including pancre-
atic, breast, non-small cell lung cancer and osteosarcoma
[7] and in cells that ectopically express active oncogenes
[8]. It is known that histone deacetylation and promoter
methylation are the mechanisms by which cancer cells
act to suppress RECK expression [9,10]. However, the
underlying mechanism of decreased RECK expression
in Ras-related tumorigenesis is still unclear. Chang HC
et al. showed that silencing RECK by Ras oncogene is
mediated by DNA methyltransferase 3b-induced pro-
moter methylation [10]. Recently, Loayza-Puch F et al.
reported that hypoxia and Ras-signaling pathways co-
operatively down-regulate RECK through miR-372/373
and miR-21 [11]. Interestingly, RECK promoter activity
suppressed by Ras through Sp1 protein binding at Sp1
binding motif has been reported [12]. Chang CH et al.
further demonstrated that induction of the Ha-rasval12
oncogene increases the binding between the HDACs-Sp1
complex and the Sp1 site on the RECK promoter to
suppress RECK expression [13]. Therefore, a better under-
standing of the underlying mechanism that enables Ras
expression to induce RECK suppression may lead to the
development of better treatments for Ras-related tumors.
The retinoblastoma binding protein 46 (RbAp46) was
initially identified as a Rb binding protein, as shown by
Rb affinity column studies [14]. RbAp46 is expressed in
the nucleus as a core component of histone deacetylase(HDAC) complexes: mSIN3, which is involved in global
transcriptional repression, and NuRD, a multi-subunit
complex exhibiting chromosome remodeling activity [15].
RbAp46 is also known as histone acetyltransferase (HAT)
type B subunit 2, formed when RbAp46 binds selectively
to histones H2A and H4; it greatly stimulates HAT activity
by recruiting HDAC enzymes to the target promoter [16].
These studies indicate that RbAp46 plays important roles
in modification and remodeling of chromatin during cell
growth and differentiation. In addition, studies also re-
vealed that RbAp46 acts as a tumor suppressor which in-
hibits the malignant phenotype of adenovirus-transformed
human embryonic kidney (HEK) 293 cells in tumor for-
mation and that RbAp46 arrests the cell cycle at the
G2/M phase [17]. Furthermore, overexpression of RbAp46
suppresses tumorigenicity of neoplastigenic breast epithe-
lial cells [18]. Constitutive expression of RbAp46 induces
the epithelial-mesenchymal transition (EMT) in mammary
epithelial cells [19]. Moreover, RbAp46 overexpression
correlates with migration of lung cancer cells and serves
as a prognostic marker for distant metastasis of non-small
cell lung cancer [20]. All together, these studies indicate
that RbAp46 plays an important role in the tumorigenesis
of various cancers. We have identified RbAp46 as a Ras
up-regulated gene using the IPTG inducible system in a
bladder cancer cell line and a NIH3T3 fibroblast variant.
It is known that RbAp46 can form a complex with HDAC
to regulate gene suppression. Ras expression induces
HDAC1 to bind with Sp1 and then suppresses RECK pro-
moter activation via the Sp1 site. Therefore we were inter-
ested in investigating the roles of RbAp46 in Ras-induced
RECK suppression and Ras-related tumorigenesis.
In this study, we demonstrated that Ras up-regulates
RbAp46 expression and then down-regulates the metas-
tasis suppressor RECK through association of RbAp46
with HDAC1 and Sp1. The RbAp46 could bind at the
Sp1 site via association with Sp1 protein and subsequently
repress RECK promoter activation. Importantly, we also
found RbAp46 increases Ras-induced MMP-9 activity and
metastasis. Our findings also showed clinical evidence




T24 (human bladder cancer cells), MCF-7 (human breast
cancer cells) and the 7–4 cells (mouse NIH3T3 fibroblast
derive) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen Life Technologies, GIBCO,
Gaithersburg, MD, USA) supplemented with 10% fetal
bovine serum (GIBCO) at 37°C in a 5% CO2 incubator.
T24 and MCF-7 cells were obtained from American
Type Culture Collection (ATCC; Rockville, MD). The
MCF-7-ras cells derived from MCF-7 contain an inducible
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mouse fibroblast NIH 3T3 cells contain the same
inducible Ha-ras val12 oncogene as that in MCF-7-ras
cells [22].
Plasmids
The mouse RECK promoter-luciferase plasmid pGL3-
RECK and Sp1 mutant plasmid, originally isolated by
Dr. Noda M. (Kyoto University, Japan) [12], were kindly
provided by Dr. Hung WC [23]. (National Sun Yat-Sen
University, Taiwan). The full-length human RbAp46 gene
(1278 base pairs) was amplified by RT-PCR. The primers
used were RbAp46 forward 5′-ATGGCGAGTAAAGA
GATGTT-3′ and RbAp46 reverse 5′-TTAAGATCCTT
GTCCCTCCA-3′. The NotI site was used to clone the
RbAp46 cDNA fragment into the pcDNA3.1 vector
(Invitrogen, Carlsbad, CA, USA) to create the plasmid
pcDNA-RbAp46. Genomic DNA extracted from transi-
tional cell papilloma RT4 cells and HPV E7 immortal-
ized uroepithelial cells were used to amplify RbAp46
promoter (Additional file 1).
Cell lysis and Western blot analysis
The cell lysates were prepared as previously described
[24]. Briefly, cells were harvested in lysis buffer (50 mM
Tris–HCl, pH 7.4, 100 mM NaCl, 2 mM EDTA, 1% NP-
40, 10 mM sodium orthovanadate, 0.1% SDS, 100 mM
phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml
pepstatin A, and 10 mg/ml leupeptin). Protein concentra-
tion was determined using the Bradford assay (Bio-Rad,
Richmond, CA, USA). Equal amounts of cellular protein
were loaded onto 10-12% sodium dodecyl sulfate (SDS)
polyacrylamide gels (SDS-PAGE). Proteins were then
transferred onto nitrocellulose membranes and the blots
were probed with the following antibodies: anti-Ras
antibody (Oncogene Science, La Jolla, CA, USA), anti-
RbAp46 antibody (Calbiochem, Gibbstown, NJ, USA),
anti-RECK antibody (MBL, Nagoya, Japan), anti-Sp1
and HDAC antibodies (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) and anti-β-actin antibody (Sigma,
St. Louis, MO, USA). The bands were detected using
enhanced chemiluminescence kit (ECL) according to
the manufacturer’s instructions (PerkinElmer, Boston,
MA, USA).
RNA extraction and RT-PCR
Total RNA of the cells was extracted using Trizol reagent
(Invitrogen, Carlsbad, CA, USA). First-strand cDNA was
synthesized from 0.2 μg to 1 μg of total RNA with the
oligo-dT primer and the Moloney murine leukemia virus
(MMLV) reverse transcriptase (Promega, Madison, WI,
USA). The conditions for PCR were conducted with the
RbAp46 or RECK primers for 30 cycles of denaturation
(94°C/1 min), annealing (60°C/1 min) and extension(72°C/1 min), followed by 1 cycle of final extension
(72°C/10 min). The conditions for β-actin were 25 cy-
cles for denaturation (94°C/30 sec), annealing (55°C/30
sec) and extension (72°C/1 min), followed by 1 cycle of
final extension (72°C/10 min). The primers used for RT-
PCR were as follows: RbAp46 forward 5′-ATGGCGAG
TAAAGAGATGTT-3′; RbAp46 reverse 5′- TGGAG
GGACAAGGA-3′; RECK forward 5′-CCTCAGTGA
GCACAGTTCAGA-3′; RECK reverse 5′-GCAGCACA
CACACTGCTGTA-3′; β-actin forward 5′-CCTGTG
GCAT CCACGAAACT-3′; β-actin reverse 5′-GAAGC
ATTTGCGGTGGACGAT- 3′. After the reaction, PCR
products were separated on a 2% agarose gel and de-
tected under UV light.
Real-time PCR
Real-time PCR reaction was performed in a total volume
of 20 μl containing 2 μl cDNA, 10 μM each of forward
and reverse primers, and 10 μl SYBR® Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA).
The cDNA in this reaction solution was denatured for
10 min at 95°C followed by 40 cycles of PCR, which in-
cluded denaturing at 95°C for 15 sec and annealing/elong-
ation at 60°C for 60 sec in the wells. Real-time PCR was
performed on the StepOne real-time PCR System (Applied
Biosystems, Foster City, CA, USA). The primers used for
real-time PCR were as follows: RbAp46 forward 5′-G
TAGGCGAGTAAAGAGATGT-3′; RbAp46 reverse 5′-T
TAAGATCCTTGTCCCTCCA-3′; PPIA forward 5′-GTT
TGCAGACAAGGTCCCA-3′; PPIA reverse 5′-ACCCGT
ATGCTTTAGGATG-3′.
Lentiviral shRNA infection
The Ha-rasval12 (TRCN0000040092) and RbAp46 (TRC
N0000038885)-specific shRNA lentiviruses were de-
signed and produced by the National RNAi Core Facility
at the Institute of Molecular Biology, Academia Sinica,
Taipei, Taiwan. The cells (3 × 105) were seeded in a 10
cm cell culture dish and incubated in DMEM medium
with 10% FBS overnight in a 5% CO2 incubator. Before
viral infection, the cells were replaced with 5 ml culture
medium containing 8 μg/ml polybrene (Sigma, St. Louis,
MO, USA), and then the virus was added to cells. After 24
hr, the medium was removed from cells, and 5 ml fresh
normal medium with 2 μg/ml puromycin (Sigma, St. Louis,
MO, USA) was added to select cells for 48 hr.
Promoter activity assay
The cells were plated onto 24-well plates (5 × 104 cells/
well) and grown overnight. The mouse RECK-luciferase
plasmid pGL3-RECK (0.2 μg) and the internal control
plasmid pRL-TK (0.025 μg) were co-transfected into the
cells using Lipofectamine 2000 reagent (Invitrogen, Life
Technologies, Inc., Grand Island, NY, USA). Luciferase
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Assay System (Promega, Madison, WI, USA) according
to the procedure suggested by the manufacturer and was
normalized for Renilla luciferase activity. Ha-ras- and
RbAp46-specific siRNA duplexes (Ha-ras 5′-TGGCTG
CACGCACTGTGGAAT-3′; RbAp46 5′-CAAUCAGCA
GA AGAUGCAU-3′), designed to target human Ha-ras
and RbAp46 were synthesized from Qiagen (Carlsbad,
CA, USA). Specific siRNAs were transfected into the
cells using Lipofectamine 2000 reagent. Luciferase activ-
ity was determined 48 hr after transfection.
Co-Immunoprecipitation
After various treatments, the cells were harvested in
lysis buffer and cellular protein extracts (200 μg) were
incubated with anti-RbAp46, anti-HDAC1 or anti-Sp1
antibodies at 4°C for 16 hr. Immuno-complexes were
collected by adding 20 μl of protein A agarose beads
(Amersham, Piscataway, NJ, USA). Samples were elec-
trophoresed on 10% SDS polyacrylamide gels and trans-
ferred to poly- vinylidene fluoride (PVDF) membranes
(Millipore, Billerica, MA, USA). Membranes were then
reacted individually with anti-HDAC1 monoclonal anti-
body, anti-RbAp46 monoclonal antibody and anti-Sp1
polyclonal antibody.
DNA affinity precipitation assay (DAPA)
DAPA was performed using streptavidin-coated beads to
bind a biotinylated DNA probe, which was used to inter-
act with nuclear extract proteins. The sequence of the
DNA probe was 5′- GCGCCGGGGGCGGGGCCTGG
TGCC-3′corresponding to the Sp1 site, originally desig-
nated as Sp1(B) in the mouse RECK promoter [12]. Nu-
clear extract proteins (200 μg) were incubated with 6 μg
of biotinylated DNA probe and 45 μl of 4% streptavidin-
coated beads at room temperature for 1 hr with constant
shaking. After centrifugation, the beads were collected
and washed three times with cold phosphate-buffered
saline. Proteins bound to the beads were eluted with
SDS-PAGE sample buffer and the binding proteins were
resolved by 10% SDS-PAGE. Immunoblotting was per-
formed as described above to examine the proteins
bound to the DNA probe.
Chromatin immunoprecipitation (ChIP) assay
The cells (2×106 cells/10 cm plate) were treated with
IPTG (5 mM, Invitrogen, Boston, MA, USA) for 24 hr,
and ChIP assay was conducted as previously described
[25]. Briefly, cells were crosslinked at 37°C for 5 min using
1% formaldehyde. After sonication, the resulting soluble
chromatin was diluted 1:10 with ChIP dilution buffer and
immunoprecipitated by anti-Sp1 antibody (Millipore,
Billerica, MA, USA), anti-RbAp46 antibody (Abcam,
Cambridge, MA, USA) or control IgG. The chromatin-antibody complexes were incubated with salmon sperm
DNA/Protein A Agarose-50% (Millipore Corp., Billerica,
MA, USA) overnight at 4°C with rotation. The DNA
was eluted from the beads using ChIP elution buffer
and purified by spin column. The primers used for de-
tection of RECK promoter were as follows: forward: 5′-
CAGCTGGCCCATAACAAAGA- 3′ and reverse: 5′-C
GGCCAGCA GAAGTA GCA- 3′.TranswellTM invasion assay
Cell invasion assay was performed in a 24-well Transwell™
(Costar, Cambridge, MA, USA). The upper chamber sur-
face of the filter was coated with Matrigel (R&D systems,
Minneapolis, MN, USA) before the experiment. The cells
were prepared (3 × 105/100 μl) with serum-free DMEM
and loaded into the upper chamber. DMEM medium
containing 10% FBS was added to the bottom chamber
as the chemoattractant. After 18 hr incubation, wet cot-
ton was used to remove the non-invaded cells from the
wells. The cells were fixed with 1% formaldehyde for 15
min at room temperature, stained with 0.1% crystal
violet for 15 min and quantified by counting the total
number of cells in four independent areas under the
light-field microscope.MMP-9 activity assay
The T24 cells with different treatments (5 × 105/well)
were seeded onto 12-well plates and filled with 500 μl
medium for 48 hr. The supernatants were collected after
centrifugation at 2500 rpm (4°C) for 10 min. MMP-9 ac-
tivity was assessed by SensoLyte® 520 MMP-9 assay kit
(ANASPEC, San Jose, CA, USA) according to the manu-
facturer’s instructions. The MMP-9 activity was monitored
at excitation/emission = 490 nm/520 nm by fluorescence
spectrometer (Thermo Scientific, Waltham, MA, USA).Experimental metastasis assay
Eight-week-old male BALB/c nude mice were obtained
from the Laboratory Animal Center, National Cheng Kung
University, Tainan, Taiwan, where they were maintained in
a pathogen-free environment throughout the study. All
animal experiment protocols were approved by the In-
stitutional Animal Care and Use Committee (IACUC),
National Cheng Kung University. The 7–4 cells, 7–4
cells treated with IPTG, or 7–4 cells carrying RbAp46
shRNA and treated with IPTG were injected through
the tail vein into the nude mice (3 × 105 cells/mice). There
were three groups, each containing five mice. Two groups
were feed with IPTG (12.5 mM) in their drinking water
during the experimental period. After three weeks, the
mice were sacrificed to evaluate the lung nodules, weight
and protein expression.
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Four pairs of human primary bladder cancer and
matched adjacent normal tissues were collected from
Chiayi Christian Hospital, Chiayi City, Taiwan. All pro-
cedures were approved by the Institutional Review
Board of Chiayi Christian Hospital (The approved No.
IRB099058), with written informed consent from all do-
nors. In addition, the specimens were coded and deleted
of all of personal information.
Statistical analysis
All data were expressed as means ± S.D. Student’s t test
was used to analyze the significance. Spearman correl-
ation was performed using GraphPad Prism 6 to show
correlations among Ras, RbAp46 and RECK.
Results
Ras up-regulates RbAp46 expression in human cancer
and mouse NIH 3T3 derivative cells
We initially identified RbAp46 gene as a Ha-rasval12 up-
regulated gene (2.7 fold increase) by suppression sub-
tractive hybridization PCR screening in the uroepithelial
cells T1R1 harboring the inducible Ha-rasval12 gene in
the presence of the inducer IPTG (Additional file 2:
Table S1). T1 also named BFTC905 was derived from a
grade III, stage D1 transitional cell carcinoma (TCC) of
urinary bladder [26]. We further showed that Ha-rasval12
expression was greatly induced compared to the un-
induced control cells and the parent cells in the presence
of IPTG. Accordingly, RbAp46 mRNA expression corre-
lated with Ha-rasval12 expression was increased (Additional
file 2: Figure S1A and S1B). We further demonstrated that
Ras expression correlates with RbAp46 expression in the
breast cancer cell MCF-7-ras, which harbors the same
inducible Ha- rasval12 oncogene [21]. The increase of
RbAp46 RNA and protein expression correlates with
Ras protein induction in a time-dependent manner in
the presence of IPTG in MCF-7-ras cells (Figure 1A and
1B). These results indicate that regulation occurs at the
mRNA level. Mouse NIH3T3 derivative 7–4 cells, which
are similar to MCF-7-ras cells also contain the same in-
ducible Ha-rasval12 gene [22], were transected with ras
siRNA for 48 hr. Under Ras-overexpressed conditions,
the expression level of Ras protein was gradually de-
creased by ras siRNA in a dose-dependent manner.
c-Met siRNA was used as a negative control. As with de-
creased Ras expression, the level of RbAp46 protein was
also gradually decreased (Figure 1C). Similarly, in the
bladder cancer T24 cells, Ras protein expression was de-
creased after transfection with ras siRNA at various
dosages. RbAp46 protein expression was decreased in a
Ras-dependent fashion, which was consistent with the
aforementioned result (Figure 1D). The above data sug-
gest that Ha-rasval12 up-regulation of RbAp46 is ageneral event. In summary, RbAp46 is a Ha-rasval12 up-
regulated gene in various cells and the regulation occurs
at the mRNA level.RbAp46 participates in the inhibitory action of Ras on
RECK expression in T24 and 7–4 cells
Sasahara et al. and Chang et al. reported that oncogenic
Ras decreases RECK expression through ERK pathway
[12,13]. Moreover, RbAp46 as a core component of
HDAC complex participates in the transcriptional re-
pression [27,28]. Therefore, we hypothesize that RbAp46
may participate in Ras-induced suppression of RECK ex-
pression. Our data showed that IPTG induced Ras ex-
pression increased RbAp46 together with suppression of
RECK mRNA expression (Figure 2A, lane 2) compared
to that in cells without IPTG induction in 7–4 cells by
RT-PCR (Figure 2A, lane 1). This inverse correlation was
further confirmed by RbAp46 siRNA under Ras overex-
pression conditions (Figure 2A, lane 3). Using bladder can-
cer T24 cells, our data consistently showed that RbAp46
protein expression was decreased and RECK protein ex-
pression was increased when Ras was suppressed by Ras
shRNA lentivirus (Figure 2B). To confirm whether RbAp46
is indeed involved in suppression of RECK expression, T24
cells were infected with RbAp46 shRNA. Our data showed
that RECK expression was increased while RbAp46 expres-
sion was suppressed. As expected, Ras protein expression
was not affected. The results indicate that RbAp46
negatively regulates RECK and Ras is an upstream regu-
lator (Figure 2C). Taken together, the above data show
that inhibition of either Ras or RbAp46 increases both
RECK mRNA and protein expression, indicating that
Ras negatively regulates RECK through RbAp46 at the
transcriptional level.
To determine how Ras and RbAp46 regulate RECK ex-
pression, mouse RECK promoter reporter plasmid pGL3-
RECK was transfected into 7–4 cells. The results showed
that the decrease of RECK promoter activity inversely cor-
relates with the gradual increase of Ras protein in a time-
dependent manner (Figure 2D, lower panel vs. upper bar
diagram). We further showed that the inhibition of RECK
promoter activity was increased in a dose-dependent fash-
ion in 7–4 cells by transfection of RbAp46 plasmid DNA
(pcDNARbAp46) (Figure 2E). To further clarify the in-
hibitory effect of RbAp46 on RECK activity, RbAp46
siRNA was used. Consistently, RbAp46 siRNA signifi-
cantly counteracted suppression of RECK promoter ac-
tivity induced by endogenous RbAp46 (pGLC3-RECK
only), Ras (pGLC3-RECK+Ras), and exogenous RbAp46
(pGLC3-RECK+RbAp46) (Figure 2F). The aforementioned
findings demonstrate that Ras is an upstream regulator of
RbAp46 which negatively regulates RECK expression at
the transcriptional level.
Figure 1 Ras up-regulates RbAp46 expression in various human cancer cell lines and in mouse fibroblast 7–4 cells. (A) MCF-7-ras
human breast carcinoma cells containing an inducible Ha-rasval12 oncogene were treated with IPTG for 48 hr to induce Ras expression. Cells
were harvested and the RNA was isolated for real-time RT-PCR analysis of RbAP46. Peptidylprolyl isomerase A (PPIA) was used for normalization
of RbAp46 mRNA levels (upper panel). Ras expression induced by IPTG was confirmed by Western blotting using anti-Ras antibody (lower panel).
β-actin was used as the internal control. (B) MCF-7-ras cells were treated with IPTG to induce Ras expression for various durations. Cell lysates
were harvested and the expression levels of Ras and RbAp46 protein were evaluated by Western blotting using anti-Ras and anti-RbAp46
antibodies. The band intensity was quantified by a densitometer. (C) The 7–4 cells were treated with IPTG and transfected with different dosages
of ras siRNA for 48 hr. The protein expression levels of Ras and RbAp46 were determined using the specific antibodies by Western blotting.
c-Met siRNA was used as the negative control. (D) T24 cells were transfected with ras-specific siRNA at different dosages. After 48 hr, the protein
expression levels of Ras and RbAp46 were determined.
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HDAC1 on SP1 site of RECK promoter in 7–4 cells
It is known that RbAp46 is a component of HDAC-
complex and Ras activation increases the binding of
HDAC1 and Sp1 to the RECK promoter at the Sp1 site
[13,15]. We showed above that Ras-induced suppression
of RECK expression is through up-regulation of RbAp46.
We therefore hypothesize that RbAp46 forms a complex
with HDAC1 and then binds with Sp1 to regulate RECK
expression via the Sp1 site of the promoter. We thus
determined whether RbAp46 formed a complex with
HDAC1 in 7–4 cells by treatment with IPTG to induce
Ras expression. The results showed that the formation
of RbAp46-HDAC1 complex was increased compared to
that in the cells without IPTG treatment as demonstrated
by co-immunoprecipitation assay (Figure 3A, lane 3 vs.
lane 1). In addition, exogenous expression of RbAp46
(pcDNA-RbAp46) also increased RbAp46-HDAC1 com-
plex formation (Figure 3A, lane 2). The reverse effect ofcomplex formation was demonstrated in the cells treated
with RbAp46 siRNA to silence RbAp46 (Figure 3A, lane
4). In contrast, Sp1 was steadily co-immunoprecipitated
with RbAp46 and HDAC1, suggesting that Sp1 is not reg-
ulated by Ras as well as RbAp46 and may function as a
docking protein for HDAC1-RbAp46 complex formation.
Furthermore, to confirm that RbAp46 suppression of
RECK promoter activity occurs through the Sp1-binding
site of the RECK promoter, the Sp1-binding site mutant of
RECK promoter reporter plasmid (pGL3-Sp1 mutant) was
used. Our data showed that no suppression of the RECK
promoter was detected with the mutated Sp1-binding site
as compared with the control (pGL3-RECK) in the pres-
ence of RbAp46 (Figure 3B). This result indicates that
RbAp46 binds with HDAC1 and Sp1 to regulate RECK
promoter at the Sp1 site.
Binding of RbAp46 complex to the RECK promoter was
further confirmed by DNA affinity precipitation assay
(DAPA) using a DNA probe of RECK promoter containing
Figure 2 RbAp46 participates in the inhibitory action of Ras on RECK expression in T24 and 7–4 cells. (A) The 7–4 cells, transfected with
or without RbAp46-specific siRNA (55.6 nM), were treated with or without IPTG for 48 hr. RT-PCR was performed using RECK- and RbAp46-specific
primer sets to measure RECK and RbAp46 mRNA levels. β-actin was used as the internal control. Ras expression was confirmed by Western
blotting. (B) T24 cells were infected with Ras shRNA lentivirus for 24 hr and selected by puromycin. A scrambled shRNA expressing GFP was used
as the negative control. The protein expression of Ras, RECK, RbAp46 and GFP was determined by Western blotting. NC: negative control. (C) T24
cells were infected with RbAp46 shRNA lentivirus as described above. Expression of various proteins was detected by Western blotting using
specific antibodies as indicated. NC: negative control. (D) The 7–4 cells that were seeded onto 24-well plates for 24 hr were transfected with RECK
promoter-luciferase reporter plasmid (pGL3-RECK) followed by IPTG treatment to induce Ras expression for the times indicated. The cell lysates
were harvested and luciferase activities were measured using the luciferase assay system (upper panel). Ras protein levels in the 7–4 cells were
analyzed by Western blotting (lower panel). (E) The 7–4 cells were co-transfected with 0.2 μg of pGL3-RECK or Vector (pGL3) and pcDNA-RbAp46
plasmids at various amounts (0.4-1.0 μg). Luciferase activity was measured 48 hr after transfection. * indicates statistical significance at p < 0.05
and ** indicates p < 0.001 by Student’s t test analysis. (F) The 7–4 cells were co-transfected with 0.2 μg of either pGL3 vector, pGL3-RECK,
pGL3-RECK + Ras or pGL3-RECK + RbAp46 cDNA, and RbAp46-specific siRNA (55.6 nM) or a control siRNA (55.6 nM). Luciferase activity was
measured 48 hr after transfection.
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the complex binding to the Sp1 site was increased when
the RbAp46 expression level was increased either by in-
creased Ras expression (Figure 3C, lane 2) or by increased
RbAp46 expression (Figure 3C, lane 4). This phenomenon
was abolished when RbAp46 siRNA was introduced into
the cells in the presence of IPTG (Figure 3C, lane 3).
Control cells without IPTG treatment showed basal
levels of RbAp46, HDAC1 and Sp1 binding (Figure 3C,
lane 1). To confirm that the RbAp46 complex indeed
binds to the RECK promoter at the Sp1 binding site
in vivo, a ChIP assay was conducted. The chromatin of7–4 cells was extracted after IPTG treatment for 24 hr.
The lysate was immunoprecipitated by Sp1, RbAp46,
and HDAC1-specific antibodies. After elution, the precipi-
tated DNA samples were screened by PCR for Sp1 binding
sequence in RECK promoter region. Our data showed that
the Sp1 sequence in the RECK promoter was amplified in
RbAp46, HDAC1, and Sp1 precipitated DNA samples
under Ras-overexpression conditions (Figure 3D). Taken
together, the above results indicate that RbAp46 forms a
complex with HDAC1 and Sp1, which binds to the Sp1
binding site in the RECK promoter to suppress RECK ex-
pression in the cell.
Figure 3 Ras overexpression increases association of RbAp46 with HDAC1 at the SP1 site of RECK promoter in 7–4 cells. (A) The 7–4
cells were transiently transfected with plasmid DNA pcDNA-RbAp46 (0.2 μg) or RbAp46-specific siRNA (55.6 nM) in the presence of IPTG for 48 hr.
After treatment, co-immunoprecipitation was conducted using anti-RbAp46, anti-HDAC1 antibodies, or anti-Sp1 antibody. (B) The cells were
co-transfected with 0.2 μg of plasmid DNA of pGL3-RECK and pGL3-Sp1 mutant in the presence or absence of pcDNA-RbAp46 plasmid. RECK
promoter activity was measured at 48 hr post-transfection. **: statistical significance at p < 0.001 by Student’s t test analysis. (C) The 7–4 cells were
transfected with pcDNA-RbAp46 (0.2 μg) or RbAp46-specific siRNA (55.6 nM) and incubated with IPTG for 48 hr. DNA affinity precipitation assay
was performed using streptavidin-coated beads to bind the biotinylated DNA probe, which was used to interact with nuclear extract proteins.
(D) The 7–4 cells were incubated with IPTG for 24 hr. Chromatin was extracted, and then immunoprecipitated by Sp1, RbAp46, or HDAC1
antibody. After elution, DNA samples were analyzed using PCR for Sp1 binding sequence in the RECK promoter region. NC: negative control.
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negatively regulates MMP-9 activity
Chang et al. reported that RECK expression inhibits cell
invasion and metastasis [29]. Since RbAp46 negatively
regulates RECK expression, the effect of RbAp46 on cell
invasion was investigated. Bladder cancer T24 cells were
infected with Ras or RbAp46 shRNA lentivirus. The GFP-
containing lentivirus was used as a positive control for
lentivirus infection efficiency and a negative control for
the experiment. Inhibition of Ras or RbAp46 by shRNA
lentiviruses significantly decreased T24 cell invasion com-
pared with the cells infected with GFP lentivirus (Figure 4A
and 4B). MMP-9 is one of the matrix metalloproteinases
(MMPs) responsible for cell invasion [7]. Chang et al.
reported that inhibition of invasion by RECK is achieved
by decreasing MMP-9 activity [29]. Therefore, we inves-
tigated whether MMP-9 activity is regulated by Ras or
RbAp46 in T24 cells. After inhibition of Ras or RbAp46
by shRNA, cell culture supernatants were collected to
evaluate MMP-9 activity using the MMP-9 assay kit
SensoLyte® 520. The results showed that MMP-9 activ-
ity was greatly decreased (>50%) in the infected T24cells by either Ras or RbAp46 shRNA compared with
that in the cells infected with GFP alone, indicating that
RECK affects MMP-9 activity through Ras or RbAp46
(Figure 4C). Our results suggest that Ras up-regulates
RbAp46 to suppress RECK expression, which leads to
increased MMP-9 activity and cell invasion.
Suppression of RbAp46 decreases metastasis of 7–4 cells
in the xenograft BALB/c nude mice model
The above in vitro data showed that suppression of
RbAp46 decreases cell invasion and inhibits MMP-9 ac-
tivity. The role of RbAp46 in vivo in Ras-induced metas-
tasis was then investigated. The 7–4 cells were infected
with RbAp46 lentiviral shRNA and stable clones were
selected. RbAp46 shRNA lentiviral clone #2 showed the
best suppression of RbAp46 (Figure 4D). The cells with
or without IPTG and/or RbAp46 shRNA were injected
intravenously (i.v.) into male BALB/c nude mice. The
mice were divided into three groups (n = 5). Two groups
(7–4 and 7-4-shRbAp46 #2) were fed with IPTG water
for three weeks. Tumor nodules were evaluated on day
21 after injection. When Ras expression was induced by
Figure 4 Silencing Ras or RbAp46 expression decreases invasive activity and lung metastasis of the bladder cancer T24 cells in nude
mice. (A) T24 cells treated with shRNA of Ras, RbAp46 or GFP lentivirus for 24 hr were seeded into matrigel-coated Transwell™ wells. Medium
containing 10% FBS was used as chemoattractant. The cells were incubated for 18 hr and the invasive cells were stained, photographed and
counted. (B) The quantification of invading cells was shown as mean ± S.D. of 9 samples from 3 independent experiments. Student’s t test was
used, *p < 0.05. (C) T24 cells were treated with shRNA of Ras, RbAp46 or GFP lentivirus for 24 hr. The supernatants were centrifuged and collected.
MMP-9 activity was measured using the SensoLyte® 520 MMP-9 assay kit. Data represent the results as mean ± S.D. of three independent
experiments. Student’s t test was used, *p < 0.05. (D) The 7–4 cells were infected with different RbAp46 shRNA lentiviral clones. The clones with
significant silencing of RbAp46 were selected. The protein expression was evaluated by Western blotting using specific antibodies. P: parental
cells. (E) The 8-week-old male BALB/c nude mice were injected intravenously with 7-4-shRbAp46 (#2) cells (3×105) through the tail vein. Mice
were sacrificed three weeks later and the lungs were collected, weighted and photographed. Arrows indicate lung nodules. (F) The lung weight
and the number of lung nodules from E were quantified. (G) The lung proteins of those mice were extracted and expression levels of Ras and
RbAp46 of five mice in each group were detected by Western blotting. Each lane represented a group of mice. *indicates statistical significance
at p < 0.05 by Student’s t test analysis.
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showed fewer nodules in the lung compared with the
number of nodules found in the other groups (Figure 4E).
Similarly, inhibition of RbAp46 reduced lung weight com-
pared with that in the other groups (Figure 4F). The lungs
of five mice from each group were combined and protein
extracts prepared to determine the expression levels of
Ras and RbAp46 by Western blotting (Figure 4G). The re-
sults showed that the expression level of Ras was inducedby IPTG (Figure 4G, lane 2) and RbAp46 was inhibited by
RbAp46 shRNA (Figure 4G, lane 3) in mice compared
with those in the control group (Figure 4G, lane 1). In
summary, our data demonstrate that inhibition of RbAp46
by shRNA in 7–4 cells decreased the number of metas-
tastic nodules induced by Ras in the nude mice model.
Taken together, we reveal that Ras-related metastasis
occurs through up-regulation of RbAp46 in the xeno-
graft mouse model.
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clinical bladder cancer tissues
To further clarify the relationships among mutant Ras (ac-
tive Ras), RbAp46 and RECK in clinical bladder cancer,
the expression levels of these three proteins in bladder
cancer specimens were evaluated by Western blotting.
High expression of Ras protein and RbAp46 protein and
low expression of RECK protein were detected in bladder
cancer specimens (Figure 5 A-D). Our data show that high
RbAp46 expression was inversely correlated with low
RECK expression in the tumor tissues compared to the
adjacent non-tumor parts in all of 4 specimens analyzed
(100%) (Figure 5A). Moreover, high expression of RasFigure 5 Interrelationships among Ras, RbAp46 and RECK in clinical b
of four clinical bladder cancer patients were evaluated by Western blotting
antibodies as indicated. β-actin was used as the internal control. N: normal
as a positive control for the expression of mutant Ras and RECK. The intens
densitometer. Quantified intensity of bands was plotting using a Spearmanprotein together with high RbAp46 expression were de-
tected in 75% of tested specimens (3/4) (Figure 5A). In
summary, we have demonstrated a correlation among Ras-
RbAp46-RECK in bladder cancer specimens (Figure 5E-
5G), indicating the importance of Ras, RbAp46 and RECK
in bladder tumorigenesis.
Discussion
Using a TCC bladder cancer cell line harboring an in-
ducible Ha-rasval12 gene [26], we identified and con-
firmed that RbAp46 is a Ras-induced gene by SSH PCR
and Northern blotting, respectively (Additional file 2:
Figure S1A and Table S1). This relationship betweenladder cancer tissues. (A) The proteins extracted from the tissue
to detect expression levels of Ras, RECK and RbAp46 using specific
tissue of bladder, and T: bladder tumor in patients. T24 cells were used
ity of bands for Ras (B), RECK (C) and RbAp46 (D) was quantified by a
correlation (E-G).
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derivative 7–4 cells, which also contain the inducible
Ha-rasval12 gene [30-32] (Additional file 2: Figure S1B).
In this study, we revealed that Ras-induced RbAp46
forms a complex with HDAC1 and Sp1, which further
binds to the Sp1 site of the RECK promoter and suppresses
its expression. The relationship among Ras, RbAp46 and
RECK expression was also detected in 75% (3/4) of the
bladder cancer specimens analyzed. This is the first report
to show that RbAp46 as a Ras up-regulated gene plays a
pivotal role in Ras-related lung metastasis through binding
of the RbAp46 with HDAC1 and Sp1 to suppress RECK
expression and activate MMP9. NIH3T3 fibroblasts were
used in this study, because of their ease to be transfected
and transformed by oncogenes.
Ahringer et al. reported that RbAp46 is a core compo-
nent of the HDAC-SIN3-NuRD complex, which partici-
pates in gene regulation through interaction with specific
co-repressors [15]. Recruitment of HDACs to promoter
regions is a general mechanism of transcriptional repres-
sion of the target genes in cells. For example, the recruit-
ment of HDACs to specific promoters could be mediated
through direct interactions with regulatory proteins such
as retinoblastoma (Rb) and metastatic-associated protein
1 (MTA1) [33-36]. Chang et al., reported that Ras overex-
pression increases the binding of HDAC1 to the Sp1 site
and suppresses RECK (metastasis inhibitor) expression
[13]. Here, we further revealed that RbAp46 utilizes Sp1
as a docking protein to recruit HDAC1 and RbAp46 and
suppresses RECK expression via the Sp1 binding site. This
result indicates that the increased binding of the RbAp46
with HDAC1 and Sp1 to the Sp1 site is dependent on the
protein level of RbAp46, which is possibly responsible for
the suppression of RECK expression. However, whether
other processes of epigenetic regulation such as acetyl-
ation or methylation are involved along with complex
formation requires further investigation. Jaejoon et al.,
reported that Sp1 and Sp3 form a complex with HDAC2
to repress human telomerase reverse transcriptase (hTERT)
expression [37]. Therefore, the possibility of the recruit-
ment of HDAC2 by RbAp46 can not be excluded. More-
over, RbAp46 is an Rb-binding protein, so it is possible that
RbAp46 could interact with Rb protein and recruit HDAC1
to the promoter.
RbAp46 overexpression induces epithelial-mesenchymal
transition (EMT) and increases the migration and inva-
sion of MCF10AT3B mammary epithelial cells [19]. Wang
et al., showed that elevated serum RbAp46 levels are
highly correlated with non-small cell lung cancer
(NSCLC) distant metastasis and knockdown of RbAp46
inhibits the migration ability of lung cancer cells [20].
Those reports indicate that RbAp46 participates in
EMT, cell migration, and invasion as well as tumor me-
tastasis. However, there is no in vivo evidence to showthe effect of RbAp46 on cancer metastasis. Our experi-
mental metastatic mouse model provides the first evi-
dence that RbAp46 participates in Ha-rasval12-induced
lung metastasis. Our finding that RbAp46 suppresses
RECK expression and decreases Ha-rasval12-induced lung
metastasis is consistent with the results of other reports
which showed that RECK protein reduces metastasis and
that down-regulation of RECK is correlated with lymph
node metastasis of lung cancer cells [29,38]. When RECK
is down-regulated, the activity of MMP-9, a key enzyme
involved in tumor invasion and metastasis, is increased
[5]. We also demonstrated that the RbAp46 expression
level positively correlates with MMP-9 activity in T24 cells
(Figure 4C). Our results provide a mechanistic link for
RbAp46 regulated cell invasion and metastasis. Collect-
ively, RbAp46 enhanced cell invasion and metastasis are
possibly caused by increased activity of MMP-9 resulting
from RECK suppression.
When oncogenic Ras is highly expressed, many down-
stream signaling pathways are activated such as Raf-1,
PI3K and Ral-GDS [2]. Previous studies showed that
oncogenic Ras and HER-2/Neu down-regulate RECK
expression through MEK/ERK signaling [12,13]. We also
revealed that Ha-rasval12 transcriptionally up-regulate
RbAp46 (Additional file 2: Figure S2A) through the Raf-
mediated MEK/ERK signaling pathway (Additional file 2:
Figure S2B). A previous study showed that Raf-MEK-
ERK1/2 pathway induced by Ha-rasval12 is necessary for
experimental metastatic ability of NIH3T3 cells [39].
Welch et al., further showed that MEK1 activation leads
to the production of MMP-2 and MMP-9 which contrib-
ute to Ras-mediated metastatic potential [40]. Therefore,
Raf/MEK/ERK signaling may play a critical role in Ras-
mediated RECK suppression and metastasis through up-
regulation of RbAp46. However, the detailed mechanism
of how RbAp46 is regulated remains to be determined.
In T24 cells, RECK protein increased dramatically after
Ras knockdown, however, there were no obvious changes
in RbAp46 (Figure 2B). This finding suggests a parallel
mechanism of Ras-induced RECK regulation. Chang et al.
reported that Ras-induced down-regulation of RECK is me-
diated via a DNMT3b/promoter methylation mechanism
[10]. Loayza-Puch et al. reported that Ras-signaling path-
ways could downregulate RECK protein through micro-
RNAs [11]. Whether DNMT3b and microRNA regulate
Ras-induced RECK downregulation independently of
RbAp46 in T24 cells is worthy of investigation. In one
bladder cancer specimen (case #358), Ras showed little
difference between normal and tumor, and yet RbAp46
was strongly upregulated in the tumor. It is possible that
endogenous Ras is regulated at the level of GDP-GTP
exchange rather than altered protein expression.
Interestingly, RbAp46 is also a potent cell growth in-
hibitor that can suppress the transformed phenotype of
Figure 6 A schematic hypothetical model shows that RbAp46 is a Ras up-regulated gene which participates in Ras-induced experimental
lung metastasis through binding with HDAC1 and Sp1 to suppress RECK expression followed by MMP-9 activation and metastasis.
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suppressor promotes malignant behaviors. RbAp46 is an
Rb-binding protein and has been proved to be a metastasis-
associated protein 1 (MTA1) complex [42,43]. Expression
of MTA1 correlates well with the metastasis potential of
human cancers [44,45]. We observed that RbAp46 can dir-
ectly interact with HDAC1. Therefore, it is possible that
RbAp46 could promote tumor metastasis by regulating
transcriptional suppression on RECK gene through histone
deacetylation activity. However, the underlying mechanism
needs to be further studied. It has been shown that
RbAp46 expression inhibits the transformation of tumor
cells by interfering with the normal cell cycle and/or en-
hancing apoptotic cell death [17]. We also found that
overexpression of exogenous RbAp46 suppressed cell
proliferation and decreased Ras-related tumor forma-
tion (unpublished data), which is consistent with previ-
ous findings [17,18,41]. RbAp48, another member of a
subfamily of nuclear WD-repeat proteins, could interact
with HDAC1 and then be recruited by Rb/E2F1 to the
promoters of E2F-regulated genes during the G1 phase
of the cell cycle [46]. It is possible that RbAp46 may
utilize similar mechanisms to suppress cell proliferation
and tumor formation.
In this study, we reveal that Ras up-regulates RbAp46
expression in human breast and bladder cancer cells as
well as in mouse fibroblast 7–4 cells, and the binding of
RbAp46 with HDAC and Sp1 represses RECK promoter
activation via the Sp1 site. Taken together, RbAp46-
induced down-regulation of RECK expression increases
cell invasion and metastasis and is accompanied with pro-
motion of MMP-9 activity. Finally, RbAp46 expression
was found to be associated with mutant Ras expression
and was inversely correlated with the expression of RECK
in bladder cancer tissues. In conclusion, our findings
provide a novel mechanism of Ras-related tumorigen-
esis in bladder cancer and suggest that RbAp46 could bea target in the treatment of Ras-related metastasis in
bladder cancer.
Conclusions
In this study, we demonstrated that Ras-induced RbAp46
expression forms a complex with HDAC1 and Sp1, which
further binds to the Sp1 site of the RECK promoter and
suppresses RECK expression. The expression levels of
Ras, RbAp46 and RECK were also determined in human
bladder cancer specimens. Our working hypothesis is that
RbAp46 is a Ras up-regulated gene which participates in
Ras-induced experimental lung metastasis through bind-
ing with HDAC1 and Sp1 to suppress RECK expression
followed by MMP-9 activation and metastasis (Figure 6).
Our findings suggest a possible therapeutic strategy
against Ras-related cancers via RbAp46 targeting.Additional files
Additional file 1: Supplementary Materials and Methods. Cloning of
full-length RbAp46 promoter; Cancer Patient Specimens.
Additional file 2: Figure S1. RbAp46 is up-regulated by Ha-rasVal12
oncogene in T1R1 human bladder cancer cell line and mouse fibroblast
7-4 cells. After the cells were treated with IPTG (5 mM) for 48 hr, the
expression levels of RbAp46 and Ras in bladder cancer cell T1R1 and the
parental cell T1were evaluated by Northern blotting. T1R1 harbors the
inducible Ha-rasval12 gene, and the parental T1 cells also named BFTC905
was derived from a grade III, stage D1 transitional cell carcinoma of urinary
bladder (Tzeng et al.). β-actin was as used as the internal control. Figure S2.
Ha-rasVal12 enhances RbAp46 promoter activity through MEK/ERK signaling
pathway. (A) The pGL3-RbAp46-E6 and -R2 of RbAp46 reporter plasmids
were co-transfected with pBSSK (1 μg) or pSGRas (1 μg) into HEK293 cells
and the luciferase activities were determined after 48 hr. The pGL3-Basic
was used as a negative vector control and pY2 containing the multiple Ets
binding sites which could be activated by Ras was used as a positive
control. (B) Inhibitors SB203580 (10 μM, for p38), PD98059 (20 μM, for
MEK) and SP600125 (20 μM for JNK) were added into HEK293 culture
medium 16 hr after transfection with pGL3-RbAp46-E6, -R2. Promoter
activity was determined by luciferase activity assay 48 hr after transfection.
Table S1. Ras up-regulated genes screened by suppression substractive
hybridization PCR screening.
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